Treatment patterns and survival of individuals with early stage non-small cell lung cancer in Germany - a study based on cancer registry data (I-O OPTIMISE / VONKO-019)
Recruiting
- Conditions
- C34Malignant neoplasm of bronchus and lung
- Registration Number
- DRKS00033794
- Lead Sponsor
- Bristol Myers Squibb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70000
Inclusion Criteria
diagnosis years 2016-2019
- place of residence in respective federal state of cancer registry
Exclusion Criteria
patient is known to the cancer registry only by means of death certificate, a pathology report, a follow up notification, a tumor conference report or a combination of the aforementioned
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment patterns in patients with early stage non-small cell lung tumor (LAM NSCLC) - from the time of diagnosis to the end of follow-up <br>(i) Description of the sequence of therapy options surgery, radiation, systemic anticancer therapy (chemotherapy, immunotherapy).<br>(ii) Classification of systemic anticancer therapy into lines of therapy according to the treatment guidelines for NSCLC.<br>For this purpose, the cancer registry data are used, which are recorded in a standardized form. For the scope and type of data collected, see the data set description in the Federal Gazette (Bundesanzeiger) 2021: BAnz AT 12.07.2021 B4
- Secondary Outcome Measures
Name Time Method Overall survival (a) from diagnosis to end of observation/ follow-up (=death or censoring [vital status alive at last linkage to registration offices in spring2022]).